Phreesia, Inc. (NYSE:PHR) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Phreesia, Inc. (NYSE:PHR) by 11.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,757 shares of the company’s stock after buying an additional 1,324 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Phreesia were worth $295,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its stake in Phreesia by 8.6% in the third quarter. FMR LLC now owns 7,856,551 shares of the company’s stock valued at $146,760,000 after acquiring an additional 624,456 shares in the last quarter. Rock Springs Capital Management LP grew its stake in Phreesia by 36.1% during the 3rd quarter. Rock Springs Capital Management LP now owns 1,776,391 shares of the company’s stock worth $33,183,000 after buying an additional 471,391 shares during the last quarter. TimesSquare Capital Management LLC grew its stake in Phreesia by 7.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 774,079 shares of the company’s stock worth $14,460,000 after buying an additional 55,793 shares during the last quarter. Blair William & Co. IL increased its position in Phreesia by 72.6% during the third quarter. Blair William & Co. IL now owns 478,414 shares of the company’s stock worth $8,937,000 after buying an additional 201,291 shares during the period. Finally, CI Investments Inc. lifted its stake in Phreesia by 6.6% in the third quarter. CI Investments Inc. now owns 477,265 shares of the company’s stock valued at $8,915,000 after buying an additional 29,500 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Stock Performance

Shares of PHR opened at $22.32 on Monday. The company has a 50-day moving average of $23.26 and a two-hundred day moving average of $21.63. The stock has a market cap of $1.26 billion, a P/E ratio of -8.86 and a beta of 0.95. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $34.98. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. The firm had revenue of $95.00 million during the quarter, compared to the consensus estimate of $93.52 million. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The company’s quarterly revenue was up 24.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.72) EPS. As a group, research analysts predict that Phreesia, Inc. will post -1.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on PHR shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a report on Thursday, March 21st. Raymond James restated an “outperform” rating and issued a $30.00 price objective (up from $25.00) on shares of Phreesia in a research note on Friday, March 15th. DA Davidson reiterated a “neutral” rating and set a $32.00 target price on shares of Phreesia in a research note on Friday, March 15th. Canaccord Genuity Group boosted their price target on Phreesia from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, March 15th. Finally, JMP Securities upped their price objective on Phreesia from $28.00 to $30.00 and gave the company a “market outperform” rating in a research note on Thursday, March 21st. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.62.

Insider Transactions at Phreesia

In related news, COO Evan Roberts sold 2,029 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $22.86, for a total transaction of $46,382.94. Following the sale, the chief operating officer now owns 754,903 shares of the company’s stock, valued at $17,257,082.58. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Chaim Indig sold 12,043 shares of Phreesia stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $272,412.66. Following the completion of the sale, the chief executive officer now directly owns 1,225,397 shares in the company, valued at $27,718,480.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Evan Roberts sold 2,029 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $46,382.94. Following the transaction, the chief operating officer now directly owns 754,903 shares in the company, valued at approximately $17,257,082.58. The disclosure for this sale can be found here. Insiders sold a total of 82,947 shares of company stock valued at $1,909,216 over the last three months. 5.80% of the stock is currently owned by insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.